Relay Therapeutics Inc（RLAY）の株式分析RLAYRelay Therapeutics Inc

Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Relay Therapeutics Inc is currently not a strong buy due to its low RSI of 25.635 indicating oversold conditions and a recent 5-day price drop of 8.95%. Although the stock has appreciated 99.02% year-to-date, the high volatility and insider selling raise caution. The main risk is the negative net income of -73,291,000 USD in Q1 2026, which could impact future performance.